Request Trial
wichy-shutterstock-com-1
Wichy / Shutterstock.com
29 October 2015EuropePhilip Webber

Are the Broad Institute’s CRISPR patents too broad?

The ability of the CRISPR/Cas9 system to make precisely targeted mutations in genes, including human genes, has taken the biotech industry by storm. It has been described by some as being the most important development in biology since the discovery of the structure of DNA by Watson and Crick in 1953.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
Report: 85% of in-house counsel want IP service providers to embrace AI
30 April 2026   Data from Questel indicates a radical restructuring of IP professionals’ duties, as adoption and demand rates continue to rise.
Europe
Moderna loses key mRNA patent in European vaccine fight
30 April 2026   The company’s rivals convinced an EPO appeals board to revoke a patent that had been used in litigation against them over Comirnaty.
Europe
EU court under pressure to define SPC limits in patent row
24 April 2026   An opinion has put pressure on the CJEU to clarify a long-running grey area that could change the game for how drug makers secure supplementary protection certificates across Europe.


Editor's picks

From the courtroom: Hikma v Amarin SCOTUS oral arguments
Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026

Editor's picks

Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026

More features

Squire Patton Boggs promotes partner to head Europe IP&T practice
From the courtroom: Hikma v Amarin SCOTUS oral arguments
Report: 85% of in-house counsel want IP service providers to embrace AI
Moderna loses key mRNA patent in European vaccine fight
CureVac targets Moderna with 10-patent suit over Spikevax
EU court under pressure to define SPC limits in patent row
Amneal acquires biopharma ahead of $300bn patent wave
Litigator from Brown Rudnick moves firms to chair practice